ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Final Issue of ‘87

December 11, 1987

June Panel Meeting Dropped

June 3, 1977

ASCO Board Accepts Plan To Establish New Bethesda Headquarters, Hire Chief Officer

April 23, 1993

Golde To Step Down At MSK; Porter Joins Hogan & Hartson.

January 26, 2001

GAO Decision Clears NCI to Deploy Medidata Rave Data Capture System

June 17, 2011

Three cancer centers joined the Multiple Myeloma Research Consortium.

September 16, 2005